RETROSPECTIVE ANALYSIS OF NIMOTUZUMAB VS CHEMOTHERAPY IN LOCALLY ADVANCED HEAD AND NECK SQUAMOUS CELL CARCINOMA PATIENTS RECEIVING CONCURRENT RADIOTHERAPY

Dr Rakesh Sharma***, Dr. Attili VS Suresh **, Dr. Mallik Singaraju *, Dr PS Dattatreya ****

* Department of Radiation Oncology, Continental Hospitals
**Department of Medical Oncology, Continental Hospitals
*** BOG National board of examinations, Delhi
****Department of Medical Oncology, Continental Hospitals

Conflicts of Interest: Nil
Corresponding author: Dr. AVS Suresh
DOI: https://doi.org/10.32553/ijmsdr.v5i6.804

Abstract:

Background: In advanced malignancies, it is important to ensure that the quality of life is not comprised, when treating the disease. Therefore there is immense need for the data on the QOL parameters for the newer agents/indications. In view of the paucity of data for the Nimotuzumab, we thought of conducting a retrospective data analysis in patients with head and neck squamous cell carcinoma.

Methods: This is a multi institutional, two arm retrospective data collection exercise done in subjects with head and neck cancer stage III or less receiving radical radiotherapy(IMRT) with either nimotuzumab or chemotherapy (weekly cisplatin) between 2015-2018 with three years follow up. Standard format for the QOL (a part of dissertation thesis by PG) was used for analysis along with demographics and outcome in terms of clinical data and survival.

Results: During the study period a total of 84 subjects were meeting the criteria for the study and the case records were retrieved with 1:1 case/control (matched population) for stage, age and other variables. Response rate was higher in the Nimotuzumab arm (86% versus 81%; P=NS). No differences were observed in median progression-free survival and overall survival. Nimotuzimab had better TWIST score of 653+238 vs 508+173 (Mean+ SD) days and better overall QOL score improvement 4.6+1.5 vs 3.1+1.3 points(Mean+ SD) compared to the cisplatin arm

Conclusions: The results indicate that, though more expensive, the Nimotuzumab scores over the conventional cisplatin (weekly) in terms of better response rates, Quality of life TWIST score and ease of administration. However retrospective nature of the data and the subject selection bias remain a major challenge for this study, which can be addressed in future prospective trials.

Keywords: concurrent, nimotuzumab, chemotherapy, head and neck cancers

Introduction:

Head and neck cancers are a significant problem in our country constituting approximately one-third of all cancer cases in contrast to 4–5% in the developed world. Surprisingly we still follow western guidelines in the management of these cancers.[1,2] However the recent efforts of researchers like Tuljapurkar et al., who compiled Indian studies made an impact and paved path for Indian guidelines changing the practice and challenged dogma in the management of head and
neck cancers in the last decade, though none of them could reach level I/II evidence.[3]

The unique difference of Indian data vs global is that

1. Majority of cancers present as locally advanced Stage III/IV disease
2. The field of Radiation is larger a
3. Responses rates are inferior
4. More cases of tobacco induced malignancy.

These things warrant exploration of the newer adjunct modalities or improvising the existing ones [4] Though NCCN and other bodies still recommend the cisplatin as the first choice in recent time we started seeing few of the EGFR inhibitors coming and occupying the list, in various indication in view of the better Overall and cancer specific survival as well as better Quality of life. [5,6,7] The same may not be applicable directly in developing nations in view of the economic constraints. However as there few economic options like “Indian version of EGF- Mab- Nimotuzumab”, we thought of analyzing the data on the same in retrospective manner to see the response and quality of life parameter (done as a part of validation of QOL questionnaire. The choice of Nimotuzumab is due to its Bivalent binding to EGFR ,(a more tumour specific action) and proven safety. There is some data on the Efficacy is proven when added to chemoradiotherapy / radiotherapy. [8] The results of this study were shared in the ESMO meeting Singapore (poster) and were published in short format [9].

**Methods**

This is a multi institutional, two arm retrospective data collection exercise done in subjects with head and neck cancer stage III or less receiving radical radiotherapy(IMRT) with either nimotuzumab or chemotherapy (weekly cisplatin) between 2015-2018 with three years follow up. Standard format for the QOL (a part of dissertation thesis by PG) was used for analysis along with demographics and outcome in terms of clinical data and survival. Patients received nimotuzumab 200 mg or chemotherapy (weekly cisplatin 40 mg /m2) along with Radiotherapy (IMRT).

Mean with Standard deviation was used to compare the both arms with P value represented for significance. We used Medcal version 7.0 for the statistical analysis.

The records were selected if they meet the following eligibility criteria

**Key Eligibility criteria- for record selection**

1. Histological proven squamous cell carcinoma of the head and neck regions
2. PS 2 or below
3. Stage III B or less at the time of initial diagnosis
4. Patients must have at least one measurable lesion as per the (RECIST) criteria and have follow-up scans done
5. Adequate Marrow, hepatic and renal functions
6. Must have completed a minimum 80% of planned therapy
7. Patients should not have had any contraindications for the therapy
8. Availability of all clinical, pathological, and QOL- related details

**Results**

During the study period a total of 84 subjects were meeting the criteria for the study and the case records were retrieved with 1:1 case/control (matched population) for stage, age and other variables. Response rate was higher in the Nimotuzumab arm (86% versus 81%; P=NS). No differences were observed in median progression-free survival and overall survival. Nimotuzimab had better TWIST score of 653+238vs 508+173 (Mean+ SD) days and better overall QOL score improvement 4.6+1.5 vs 3.1+1.3 points(Mean+ SD)compared to the cisplatin arm

The details of the same were described in table-1 . The selection of case records was depicted in the figure 1
## Table 1: Demographics, response rates and QOL of the two arms

| Character                      | Nimotuzumab+RT | Csiplatin+RT | P value |
|-------------------------------|----------------|--------------|---------|
| Number of subjects            | 42             | 42           | NS      |
| Age (Median+SD)               | 34.6+12.6      | 38.2+11.8    | NS      |
| Male:Female                   | 29:13          | 28:14        | NS      |

### Major adverse events

| Event                        | Nimotuzumab+RT | Csiplatin+RT | P value |
|------------------------------|----------------|--------------|---------|
| Neutropenia                  | 26(62%)        | 31(73%)      | NS      |
| Nausea/Vomiting              | 31(73%)        | 38(90%)      | NS      |
| Rash                         | 12(29%)        | 1(2%)        | 0.01    |
| Mucositis                    | 27(64%)        | 29(69%)      | NS      |

### Response to therapy

| Status                        | Nimotuzumab+RT | Csiplatin+RT | P value |
|-------------------------------|----------------|--------------|---------|
| Stable disease                | 6 (14%)        | 8 (19%)      | NS      |
| Complete response             | 18 (43%)       | 12 (29%)     | 0.05    |
| Partial response              | 12 (29%)       | 14 (33%)     | NS      |
| Progressive disease           | 6 (14%)        | 8 (19%)      | NS      |

### Survival

| Survival                      | Nimotuzumab+RT | Csiplatin+RT | P value |
|-------------------------------|----------------|--------------|---------|
| Survival                      | 32.4+6.9       | 26.6+5.6     | 0.04    |

### Quality of life parameters

| Parameter                    | Nimotuzumab+RT | Csiplatin+RT | P value |
|------------------------------|----------------|--------------|---------|
| QOL change                   | 4.6+1.5        | 3.1+1.3      | 0.03    |
| TWISTT (in days)             | 653+238        | 508+173      | 0.03    |

Total 121 subject records were pulled who met the criteria with head and Neck Cancer.

42 had Completed Biological therapy + RT as planned (Nimotuzumab)

42 s had Completed CT + RT as planned (Cisplatin 40 mg/m2 weekly)

37 subjects records were deleted with incomplete data.

Figure 1: Distribution of cases among the arms and method of selection
Discussion

A clear and significant observation made in this study is the significant betterment of Quality of life and lesser side effects with higher response rates (though statistically non significant) in the nimotuzumab arm in association with chemoradiation. The response rates are much higher in bulky disease compared to the cisplatin arm, which makes this more attractive option.

We also observed lesser frequency and intensity of the adverse reactions in the nimotuzumab arm compared to the cisplatin arm. The results indicate that, though more expensive, the Nimotuzumab scores over the conventional cisplatin (weekly) in terms of better response rates, Quality of life TWIST score and ease of administration for patients with HNSCC receiving definitive Radiotherapy and had better QOL and TWIST.

While Small sample size, Single institution study, Non randomized design and Retrospective analysis are major limitations of this study, the significant p value is a point to be noted in terms of response rates and quality of life.

A prospective study was planned and submitted to the local ethics committee based on above results to validate these results. If the trends are proven, this could be a choice with patients having borderline renal function and poor performance status.

References

1. Snehal Bhupesh Shah, Shilpi Sharma, and Anil Kieth D’Cruz. Head and neck oncology: The Indian scenario. South Asian J Cancer. 2016; 5(3): 104–105.
2. P. Joshi, S. Dutta, P. Chaturvedi, S. Nair Head and neck cancers in developing countries. Rambam Maimonides Med J, 5 (2) (2014), p-9
3. Vidisha Tuljapurkar, Harsh Dhar, Aseem Mishra, Swagnik Chakraborti, Pankaj Chaturvedi, Prathamesh S Pai. The Indian scenario of head and neck oncology - Challenging the dogmas. South Asian J Cancer. Jul-Sep 2016;5(3):105-10
4. B.K. Mohanti, P. Nachiappan, R.M. Pandey, A. Sharma, S. Bahadur, A. Thakar Analysis of 2167 head and neck cancer patients’ management, treatment compliance and outcomes from a regional cancer centre, Delhi, India J Laryngol Otol, 2007; 121 (1), 49-56.
5. Stokes WA, Sumner WA, Breggren KL, Rathbun JT, Raben D, McDermott JD. A comparison of concurrent cisplatin versus cetuximab with radiotherapy in locally-advanced head and neck cancer: A bi-institutional analysis. Rep Pract Oncol Radiother. 2017;22(5):389-395.
6. RonyBenson SupriyaMallick P.K.Julka G.K.Rath. Anti EGFR therapy in the treatment of non-metastatic head and neck squamous cell carcinoma: The current evidence. 2016;28(3),141-148.
7. F. Petrelli, A. Coinu, V. Riboldi, K. Borgonovo, M. Ghilardi, M. Cabiddu, et al. Concomitant platinum-based chemotherapy or cetuximab with radiotherapy for locally advanced head and neck cancer: a systematic review and meta-analysis of published studies Oral Oncol, 2014; 50 (11), 1041-1048.
8. Reddy BK, Lokesh V, Vidyasagar MS, Shenoy K, Babu KG, Shenoy A, et al, Nimotuzumab provides survival benefit to patients with inoperable advanced squamous cell carcinoma of the head and neck: a randomized, open-label, phase IIb, 5-year study in Indian patients. Oral Oncol. 2014;50 (5):498-505.
9. Vs Attili, S, Mallik, S , K Dadireddy, P and Pawar, D. Evaluation of quality of life (QOL) and time without symptom and treatment toxicity of nimotuzumab vs chemotherapy (weekly cisplatin) concurrently with with radiotherapy in patients with head and neck squamous cell carcinoma. Annals of Oncology. 2017; 28; 10; 1093; (362P)